Cargando…
Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity
SIMPLE SUMMARY: Due to the nonspecific nature of disease symptoms and late diagnosis, prognosis for ovarian cancer remains poor, while its incidence is increasing dramatically. Current treatment options lead to recurrence for over 80% of patients, and there is a real and urgent need to identify new...
Autores principales: | Jeanne, Albin, Sarazin, Thomas, Charlé, Magalie, Moali, Catherine, Fichel, Caroline, Boulagnon-Rombi, Camille, Callewaert, Maïté, Andry, Marie-Christine, Diesis, Eric, Delolme, Frédéric, Rioult, Damien, Dedieu, Stéphane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508526/ https://www.ncbi.nlm.nih.gov/pubmed/34638503 http://dx.doi.org/10.3390/cancers13195019 |
Ejemplares similares
-
Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide
por: Jeanne, Albin, et al.
Publicado: (2017) -
Identification of TAX2 peptide as a new unpredicted anti-cancer agent
por: Jeanne, Albin, et al.
Publicado: (2015) -
Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality?
por: Galissier, Thibaut, et al.
Publicado: (2016) -
LRP1 expression in colon cancer predicts clinical outcome
por: Boulagnon-Rombi, Camille, et al.
Publicado: (2018) -
Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017)